News headlines about Juno Therapeutics (NASDAQ:JUNO) have trended somewhat positive on Monday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Juno Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.4425052291951 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern’s scoring:
- Juno Therapeutics, Inc. (JUNO) Coverage Initiated at Barclays PLC (americanbankingnews.com)
- CAR-T Mania: Could Juno Therapeutics Get Acquired Next? – Motley Fool (fool.com)
- Insider Selling: Juno Therapeutics, Inc. (JUNO) Director Sells 12,000 Shares of Stock (americanbankingnews.com)
- Technical Snapshots for These Biotech Stocks — ZIOPHARM Oncology, Zosano Pharma, Juno Therapeutics, and Lexicon Pharma (bizjournals.com)
- Notable ETF Inflow Detected – XBI, JUNO, EXEL, ACAD – Nasdaq.com – Nasdaq (nasdaq.com)
A number of research firms have recently weighed in on JUNO. Vetr upgraded shares of Juno Therapeutics to a “buy” rating in a report on Tuesday, May 23rd. Wedbush restated a “neutral” rating and issued a $24.00 target price on shares of Juno Therapeutics in a report on Tuesday, June 6th. Wells Fargo & Company restated an “outperform” rating and issued a $54.00 target price (up from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 20th. Finally, Zacks Investment Research upgraded shares of Juno Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 5th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $34.88.
Juno Therapeutics (JUNO) opened at 41.85 on Monday. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $44.60. The stock’s market capitalization is $4.39 billion. The company’s 50 day moving average is $32.06 and its 200-day moving average is $26.37.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same quarter in the previous year, the business posted ($0.64) earnings per share. Juno Therapeutics’s revenue for the quarter was down 22.8% on a year-over-year basis. Analysts forecast that Juno Therapeutics will post ($3.12) earnings per share for the current fiscal year.
In other news, Director Anthony B. Evnin acquired 9,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was purchased at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the completion of the transaction, the director now owns 66,301 shares in the company, valued at $1,617,744.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the firm’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,078,369 shares of company stock valued at $218,620,477. 15.26% of the stock is owned by company insiders.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.